Thorsten Sadowski

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

Sanofi-a Ventis Deutschland Gmbh

where one patent can have more than one assignee

Years Active: 2014-2023

where 'Filed Patents' based on already Granted Patents

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11807905 - Growth differentiation factor 15 as biomarker for metformin (2023-11-07),

2. 10975434 - Growth differentiation factor 15 as biomarker for metformin (2021-04-13),

3. 9751858 - 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2017-09-05),

4. 9353068 - 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2016-05-31),

5. 9199947 - Biaryl-propionic acid derivatives and their use as pharmaceuticals (2015-12-01),

6. 9174952 - Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals (2015-11-03),

7. 9150526 - Biaryl-propionic acid derivatives and their use as pharmaceuticals (2015-10-06),

8. 9120783 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2015-09-01),

9. 9029559 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2015-05-12),

10. 8962671 - Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2015-02-24),

11. 8669370 - Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2014-03-11),

12. 8664257 - Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals (2014-03-04),

Title: Thorsten Sadowski: Pioneering Innovations in Biomarkers for Metformin Treatment

Introduction

Thorsten Sadowski, based in Frankfurt am Main, Germany, is a notable inventor in the field of biomedical innovations. With a substantial portfolio of 12 patents, Sadowski has made significant contributions to the understanding and application of biomarkers, particularly in relation to metformin treatment. His latest inventions reflect cutting-edge approaches to enhance patient care.

Latest Patents

Among Sadowski's most impactful patents is his work on "Growth differentiation factor 15 as biomarker for metformin". This invention revolves around metformin’s application for treating patients who show an increased level of GDF15 in response to the medication. His patented methods include identifying which patients will benefit from metformin treatment, adapting dosages accordingly, and utilizing GDF15 as a predictive biomarker. Furthermore, he has developed kits for identifying patients suited for metformin therapy, showcasing his deep commitment to tailoring treatments to individual needs.

Career Highlights

Sadowski's career features significant positions in well-known companies such as Sanofi and Sanofi-Aventis Deutschland GmbH. His work has contributed to advancements in pharmaceutical applications, particularly concerning diabetes treatment and metabolic disorders.

Collaborations

Throughout his career, Sadowski has worked alongside esteemed colleagues, including Sven Ruf and Herman Schreuder. These collaborations highlight the teamwork and shared vision that fosters innovation in the realm of health sciences.

Conclusion

Thorsten Sadowski stands out as a remarkable inventor whose work continues to shape the future of medical treatments. With a focus on personalized medicine and biomarkers, his contributions not only advance scientific knowledge but also enhance patient outcomes in metformin therapy. The ongoing impact of his patents underscores the vital role of innovative thinkers in healthcare.

This text is generated by artificial intelligence and may not be accurate.